Launches First Non-Radioactive Test Kit for High Throughput hERG Channel Blockage Screening CARLSBAD, Calif.–Invitrogen Corporation (NASDAQ:IVGN), a leading provider of essential life sciences technologies for research, production and diagnostics, today announced the availability of a proprietary test kit that enables better screening for cardiotoxicity traits of potential drug compounds earlier in the discovery process. The Predictor™ hERG Fluorescence Polarization Assay Kit is the first commercially available non-radioactive, homogenous assay kit for high-throughput screening of compounds interacting with the hERG ion channel. Drug-induced heart dysrhythmias and adverse effects have been linked with blockage of the human ether-a-go-go related gene (hERG) channel. Lethal cardiotoxic side effects of several blockbuster drugs have led to the U.S. Food and Drug Administration’s requirement that all new small-molecule drug compounds be tested for hERG channel blockage, typically using a technique called electrophysiology patch-clamp analysis. “Pharmaceutical researchers are continually seeking to improve their assessment of compound safety, particularly if they can shift that work to earlier in the drug discovery process and also do it in a cost-effective way,” said Dr. Brian Pollok, Chief Scientific Officer for Invitrogen. “The Predictor hERG assay delivers a novel solution that is accurate, efficient and convenient for determining potential hERG liability of compounds.” Patch-clamp analysis is costly and slow to perform; therefore most companies narrow the number of compounds they test with patch-clamp analysis with screening assays that are less expensive and less time-consuming. Currently, drug developers use radioligand displacement assays as the primary screen for reducing the number of patch-clamp analyses. Invitrogen’s Predictor™ hERG assay eliminates radioactivity and allows researchers to rapidly and accurately triage compounds for more detailed patch-clamp analysis. In addition, the Predictor™ hERG assay results are highly predictive of patch-clamp data, much faster and considerably less expensive than current radioligand displacement tests. For more information please visit www.invitrogen.com/predictor. Invitrogen will also offer the SelectScreen™ hERG Binding Assay Service, as part of its SelectScreen™ family of services. Safe Harbor Statement Certain statements contained in this press release are considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen’s intent that such statements be protected by the safe harbor created thereby. Potential risks and uncertainties include, but are not limited to a) the Predictor™ hERG Fluorescence Polarization Assay Kit may improve quality and reduce time and expenses related to screening for drug toxicity traits; and b) the market may not accept the company’s products and services, as well as other risks and uncertainties detailed from time to time in Invitrogen’s Securities and Exchange Commission filings.